BARD1 | CYP2D6 | FLT3 | LMO1 | PARP1 | RHOA | TOP2A | ||
BAX | CYP3A4*4 | FLT4 | LRP1B | PARP2 | RICTOR | TP53 | ||
BCL2 | CYP3A5 | FOXA1 | LYN | PAX5 | RNF43 | TP63 | ||
BCL2L11(BIM) | CYSLTR2 | FOXL2 | LZTR1 | PBRM1 | ROS1 | TPMT | ||
BCR | DAXX | FOXP1 | MAP2K1(MEK1) | PDCD1(PD1) | RPTOR | TSC1 | ||
BIRC3 | DDR2 | FRG1 | MAP2K2(MEK2) | PDCD1LG2(PD-L2) | RRM1 | TSC2 | ||
BLM | DENND1A | GATA1 | MAP2K4 | PDE11A | RUNX1 | TSHR | ||
BMPR1A | DHFR | GATA2 | MAP3K1 | PDGFRA | RUNX1T1 | TTF1 | ||
BRAF | DICER1 | GATA3 | MAP3K4 | PDGFRB | SBDS | TUBB3 | ||
BRCA1 | DLL3 | GATA4 | MAX | PDK1 | SDC4 | TYMS | ||
BRCA2 | DNMT3A | GATA6 | MCL1 | PGR | SDHA | U2AF1 | ||
BRD4 | DOT1L | GNA11 | MDM2 | PHOX2B | SDHB | UGT1A1 | ||
BRIP1 | DPYD | GNAQ | MDM4 | PIK3C3 | SDHC | VAMP2 | ||
BTG2 | DTL(CDT2) | GNAS | MECOM | PIK3CA | SDHD | VEGFA | ||
BTK | DUSP2 | GRIN2A | MED12 | PIK3CD | 9-Sep | VHL | ||
BUB1B | EGFR | GRM3 | MEF2B | PIK3R1 | SETBP1 | WAS | ||
c11orf30 | EIF1AX | GRM8 | MEN1 | PIK3R2 | SETD2 | WISP3 | ||
CASP8 | EP300 | GSTM1 | MET | PKHD1 | SF3B1 | WRN | ||
CBL | EPAS1 | GSTM4 | MGMT | PLAG1 | SGK1 | WT1 | ||
CBLB | EPCAM | GSTP1 | MITF | PLCB4 | SKP2 | XPA | ||
CCND1 | EPHA2 | GSTT1 | MLH1 | PLK1 | SLC34A2 | XPC | ||
CCNE1 | EPHA3 | HDAC2 | MLH3 | PMS1 | SLC3A2 | XRCC1 | ||
CD274(PD-L1) | EPHA5 | HDAC9 | MLLT1 | PMS2 | SMAD2 | XRCC2 | ||
CD74 | ERBB2(HER2) | HGF | MLLT3 | POLD1 | SMAD3 | YAP1 | ||
CDA | ERBB2IP | HLA-A | MLLT4 | POLD3 | SMAD4 | ZNF217 | ||
CDC73 | ERBB3 | HNF1A | MPL | POLE | SMAD7 | ZNF703 | ||
CDH1 | ERBB4 | HNF1B | MRE11A | POLH | SMARCA4 | |||
CDK10 | ERCC1 | HRAS | MSH2 | POT1 | SMARCB1 | |||
Key genes for targeted drug use | ||||||||
Key genes for chemotherapy | ||||||||
Genetic risk prediction genes | ||||||||
Important tumor-driving genes, but there are no targeted drugs at present | ||||||||
Key genes in the tumor-related signaling pathways | ||||||||